Indexed with PubMed and Science Citation Index (E) 
Users online: 3101 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
    Next article
    Previous article
    Table of Contents

    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal


Year : 1993  |  Volume : 59  |  Issue : 4  |  Page : 194--196

Intralesional interferon alpha - 2b in genital warts : A preliminary study

Correspondence Address:
R K Pandhi

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Currently available therapy for condyloma acuminata (genital warts) is not consistently effective. Interferon (IFN) has both antiproliferatve and antiviral properties and has been used to treat genital warts with varying degree of success. We conducted an open study on 6 male patients with genital warts. A single wart of comparable area from each patient was injected with 2 106 IU of IFN alpha-2b, 3 times weekly for 3 weeks. The response to treatment was assessed during the therapy and at 1, 5 and 9 weeks after the completion of treatment. Two of the injected lesions showed complete regression and in 2, there was a moderate reduction in size but not a complete regression. In 2 patients there was appearance of new lesions while still on therapy and only a slight reduction tn the size of injected lesions. All patients tolerated the therapy well and in none treatment had to be discontinued due to adverse reactions. The preliminary trial suggests that intralesional IFN is not a superior alternate to the currently available modalities of treatment in genital warts. High cost of the therapy is another limiting factor.

[FULL TEXT] [PDF Not available]*

Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow